ELMWOOD PARK, N.J., April 1, 2021 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced a COVID-19 testing agreement for players and staff, stadium employees and league staff for the 2021 Major League Baseball (MLB) season. Under the agreement with MLB, BioReference will provide on-site rapid PCR point-of-care COVID-19 testing to all […]
Search Results for: care
01
Apr
Apr
As the COVID-19 pandemic continues, and vaccines become more readily available to the general population, you may be left wondering whether or not you carry the antibodies. But what are antibodies? How are antibody tests used? Are you immune? What are Antibodies? Antibodies are proteins produced during the body’s immune response to infection. If you […]
SPOKANE, Wash., March 30, 2021 /PRNewswire/ — Gestalt Diagnostics today announced, that BioReference Laboratories Inc., an OPKO Health company, has selected their digital pathology solution, PathFlow®, to support its pathology business. PathFlow is an enterprise software platform specifically designed to bring the benefits of digital workflow to pathologists and pathology laboratories. Under the agreement, Gestalt is partnering […]
BioReference is currently testing students and staff from two of the five largest school districts in the nation and is prepared to rapidly expand COVID-19 school testing to other school districts across the country ELMWOOD PARK, N.J., March 26, 2021 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the expansion of its COVID-19 school […]
11
Mar
Mar
March is National Kidney Month, a time to raise awareness about kidney disease. What are the kidneys and what do they do? Kidneys are two bean-shaped organs, located near the middle of the back, just below the rib cage. Kidneys are a filtering system, which filter about 200 quarts of blood each day. They remove […]
03
Mar
Mar
Apart from skin cancer, colorectal cancer is the third most common cancer diagnosed in the U.S. for both men and women. With well over an estimate of 100,000 new cases for colon, and over 45,000 new cases for rectal cancer.* March is Colorectal Cancer Awareness Month – an opportunity to educate about colon and rectum […]
26
Feb
Feb
By Patrick, Sr. Sales Director BioReference is proud to introduce BioDiversity & Inclusion: myPerspective, featuring inspiring stories contributed by our employees. This month we celebrate Black History Month with a story about Dr. Ernest Everett Just, by Patrick. Impactful contributions by African-Americans are extremely vast, especially in the field of diagnostic medicine and science. There […]
Crain’s New York Business – Health Pulse Plus: Oscar launches IPO that could be worth $1.1B AdvantageCare opens Flushing gastroenterology office BioReference, New York Forward partner to offer more rapid tests In assessing Covid-19 vaccination, testing, hospitalization, death and transmission rates, New York came in 49th out of all the states and Washington, D.C., according […]
Wall Street Journal Barclays Center, Madison Square Garden to welcome back fans this week—under capacity limits and as long as the spectators test negative When fans head to the Barclays Center on Tuesday, they will be entering a space where everyone around them, from NBA players to security guards, has tested negative for Covid-19. It […]
Press Release
New York State Partners with BioReference Laboratories to Spearhead the NY Forward COVID-19 Rapid Test Program to Help Reopen the New York Economy
22
Feb
Feb
Locations now open in NYC with more to follow across the State NEW YORK CITY, February 22, 2021 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), announced its participation in the NY Forward Rapid Testing Program and opened eight locations offering COVID-19 rapid testing around New York. This program is designed to provide New Yorkers, and those visiting, with inexpensive and rapid COVID-19 testing. NY Forward is a collaboration with The Empire State Development Corporation, The Real Estate Board of New York (REBNY), the […]
